Market Intelligence, Target Validation, and High-Purity Reagents for Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PPP1R3B drug discovery targeting hepatic glucose metabolism. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PPP1R3B Full-Length & Scaffold Mutant Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. |
View PPP1R3B Products |
| Gene Delivery | PPP1R3B Promise-ORF / Lentivirus Full-length ORF for hepatocyte stable cell lines. CMV/EF1a promoter options. |
View PPP1R3B Products |
| Benchmark Ab | Anti-PPP1R3B (Rabbit Recombinant Monoclonal) High-affinity positive control for Co-IP and Western Blot. |
View PPP1R3B Products |
| Validator | PPP1R3B siRNA Set For knockdown verification in glycogen metabolism assays. |
View PPP1R3B Products |
| PPP1CA | PP1 Alpha Catalytic Subunit Direct binding partner. Essential for phosphatase holoenzyme reconstitution. |
View PPP1CA Products |
| GYS1/2 | Glycogen Synthase (muscle/liver) Downstream substrate of PPP1R3B-PP1 complex. Critical for pathway readouts. |
View GYS1 Products / View GYS2 Products |
| PPP1R3C | Paralog regulatory subunit Key for paralog selectivity counter-screening. |
View PPP1R3C Products |
| GSK3B | Glycogen Synthase Kinase 3 Beta Upstream regulator of glycogen metabolism. Used for combination therapy studies. |
View GSK3B Products |
| PPP1R3D | Paralog regulatory subunit Distinct tissue expression; important for off-target profiling. |
View PPP1R3D Products |
Critical Assay Challenges and TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PPI validation & holoenzyme reconstitution | High-purity PPP1R3B & PPP1CA proteins. Endotoxin <1 EU/µg. HEK293 expressed for native folding. |
| Paralog selectivity (PPP1R3A/C/D/E) | Homolog panel proteins strictly verified by mass spec for off-target profiling. |
| Disease variant structural validation | Mutant recombinant proteins (domain truncations & binding mutants). Exact theoretical MW. |
| Knockdown specificity & cellular controls | Validated siRNA included for knockdown confirmation in hepatocyte models. |
| Cross-species metabolic translation | Human/Mouse/Rat ortholog proteins available with >95% purity. |
| Intracellular localization & scaffold integrity | Sequence verified ORFs ensuring native conformation and proper scaffold assembly. |
Global Clinical Landscape & Future Outlook
The metabolic disease field is increasingly scrutinizing glycogen-regulatory scaffolding proteins as druggable intracellular nodes. PPP1R3B (also known as PTG) anchors PP1 to glycogen particles, representing a structurally unique entry point for liver-selective metabolic modulation. Beyond traditional metabolic interventions, the next wave of R&D is targeting protein-protein interaction (PPI) inhibitors, RNA therapeutics (siRNA/ASO), and targeted degradation (PROTACs) for indications including MASLD, type 2 diabetes, Lafora disease, Pompe disease, and hepatic glycogen storage disorders. While still in early validation stages, PPP1R3B is positioned as a differentiated target for both rare genetic glycogenoses and common metabolic diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Consortia, Metabolic Biotechs | MASLD, Type 2 Diabetes, Lafora Disease | Reconstituted Holoenzyme Assay (Need PPP1R3B + PP1 complex) |
| siRNA / ASO / Gene Silencing | RNAi Focus Companies, Metabolic Validation Programs | Hepatic Glycogen Storage Disorders, MASH | Knockdown Validation (Need validated siRNA & Benchmark Abs) |
| Gene Therapy | Rare Disease Specialists, Gene Therapy Companies | Glycogen Storage Disease Type 0, Pompe Disease | Functional validation in hepatic cell models (Need Lentivirus for stable expression) |
| Allosteric Peptide / Biologic | Early-Stage Biotech | Congenital Hyperglycemia, Hepatic Insulin Resistance | Thermal Shift & Co-IP (Need full-length protein with native conformation) |
| PROTACs | Targeted Degradation Innovators | Metabolic Disorders | Ternary Complex Formation (Need customized tags & native MW validation) |
Live PPP1R3B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: